heavy solute load in cow's milk is presented to kidneys with a relative functional immaturity.
Though the changes which occur in serum calcium and magnesium levels in the neonatal period have been studied by others (Gittleman et al., 1964; Harvey et al., 1970) , there is little agreement on the precise values which should be accepted as abnormal. A serum calcium level of 7 mg/100 ml or below was chosen in this paper, and this is lower than has generally been accepted in the past (Keen, 1969) . No attempt has been made to define accurately normal serum magnesium levels. Harvey et al. (1970) , using atomic absorption spectrophotometry, showed a mean serum magnesium concentration of 1-4 mg/100 ml in 25 bottle-fed babies on the sixth day of life. However, the range of results was very wide, 0-85-1 9 mg/100 ml. Suffice to note that the oedematous babies had abnormally low levels for this laboratory, as did several of the non-oedematous babies with the lower serum calcium levels.
The positive correlation between calcium and magnesium levels was apparent only in the babies who were not oedematous. There is conflicting evidence concerning the role of parathyroid hormone in magnesium metabolism (Jones and Fourman, 1966) . However, the case of a newborn baby with congenital absence of the parathyroid glands, described by Taitz et al. (1966) , supports the view that serum calcium and magnesium levels are influenced in the same way by parathyroid hormone, as this baby had tetany associated with hypocalcaemia and hypomagnesaemia.
The rise in the serum magnesium levels which was seen in the non-oedematous babies when calcium supplements were given has been noted previously in hypocalcaemic babies (Gittleman et al., 1964) . It may be that the correction of the hypocalcaemia in these babies allows magnesium to be released from bone and muscle, in keeping with the view that there is a common transport mechanism for calcium and magnesium (Alcock and Maclntyre, 1962) .
With regard to the six oedematous babies, the fact that the serum magnesium levels were abnormally low, that there was no correlation between magnesium and calcium levels, and that magnesium levels did not rise on giving calcium supplements, suggests that there was some other factor influencing the magnesium levels. The low magnesium levels cannot be explained by a lowered protein-bound magnesium fraction, as the total protein and albumin levels were similar in the oedematous and non-oedematous babies.
Aldosterone favours renal excretion of magnesium, and increased renal excretion rates of magnesium have been found in primary aldosteronism (Mader and Iseri, 1955) , and may also occur in secondary aldosteronism (Kobayashi and Shiraki, 1967) . It may be that secondary aldosteronism, induced by the transient fluid retention, influenced the serum magnesium levels in the oedematous babies under study. The low plasma sodium and normal plasma potassium levels are consistent with secondary aldosteronism in association with fluid retention (Johnston, 1969) . Though (Fig. 1) , the 54 patients reported to the C.S.D. (Fig. 2) ., and the 74 patients recorded in the literature (Fig. 3 ), all of whom had had a previous general anaesthetic. The data show an "itexcess" 2of patients who had had repeat operations within short intervals of up to four weeks in the jaundiced patients in Figs. 2 and 3 relative to those in Fig. 1 , and a "deficiency" for longer intervals. In other words the cases in the C.S.D. and in the literature (Figs. 2 and 3 ) have a very much higher proportion of short interval repeat halothane anaesthetics than does the general population (Fig. 1) A study of the postmortem records for the whole hospital for that period showed that 15,088 patients had a necropsy. Out of this very large total we found 18 cases of acute hepatic necrosis, only three of which were post-surgical. One case, already reported (Mushin et al., 1964) , died after two nonhalothane anaesthetics, another after two halothane anaesthetics within a month (this case is among those reported to the C.S.D.), and the third after one anaesthetic, probably with halothane, in a hospital outside our area. In the last case the postmortem report attributed the acute hepatic necrosis to Clostridium welchii septicaemia, and this case is therefore excluded from our calculations. There is, therefore, an incidence of one case of hepatic necrosis in about 6,000 halothane anaesthetics repeated within a month. We previously (Mushin et al., 1964) examined in detail the incidence of unexplained jaundice after halothane in our hospitals and found no other cases, apart from the second one above. Since then we have not seen any other cases; therefore, this one case represents our total incidence during a period of more than 10 years.
Extrapolation of our Survey to the Surgical Population of England and Wales
The age distribution of the surgical patients (10, 108) (Table III) (General Register Office, 1958-68) . Considering the rapid increase in the use of halothane in this period some effect might have been expected if fatal cases of jaundice after halothane were being certified in these categories.
Cases Reported to Committee on Safety of Drugs The number of reports a year and the number of deaths a year is shown in Table IV . The peak in 1968 includes nine cases (two deaths) reported from one hospital. Even apart from that year, it is possible that there is a trend in an upward direction of both reports and deaths. This is partly to be expected if the proportion of patients given halothane in the country as a whole is rising. The actual number of reports and deaths is, however, very small indeed and does not parallel the increased use of halothane. 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 England and Wales .
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Conclusions
There is a significant association between the occurrence of post-halothane jaundice and a previous administration of halothane when the interval between the two halothane anaesthetics is four weeks or less. The risk is in any case small and seems to lie between 1 case in 6,000 (Cardiff data) and 1 case in 22,000 (average of C.S.D. data) repeat halothane anaesthetics within four weeks. In the case of patients who had not had halothane within the previous four weeks the risk is smaller still. From the C.S.D. data it appears to be less than 1 in 600,000. On the assumption that the average consultant anaesthetist administers 1,000 anaesthetics per annum and that if all the patients having second anaesthetics within four weeks were given halothane, in a working life of 30 years he will have administered such repeat halothane anaesthetics to about 2,000 patients. Most therefore of the consultant anaesthetists in the British Isles are likely to complete their professional lives without seeing a single case of halothane jaundice.
There seems therefore little reason, on present evidence, to stop halothane anaesthesia. Nevertheless, and in spite of the rarity of jaundice, it is reasonable to avoid halothane when it has been administered to the same patient during the previous four weeks. However, this advice assumes that there is an equally effective and safe alternative with which the anaesthetist is familiar. Otherwise it might mean that by avoiding a rare cause of morbidity or mortality a more common one is introduced.
Introduction
The use of whole-body radioactivity monitors has facilitated the measurement of blood losses (Price et al., 1962 (Price et al., , 1964 Holt et al., 1967; Will et al., 1970a 
P:atients and Methods
The MERLIN mobile whole-body radioactivity monitor (Boddy, 1967) of the Scottish Universities Research Reactor Cer.tre was used. The monitor has a shadow shield of 7 tons (7,112 kg) of lead with a sodium detector, 29,2 cm diameter by 10-2 cm depth, in a central turret. Lying on a motorized couch, the subject passes beneath the detector in the supine and then in the prone position. Output pulses from the detector are taken to a T.M.C. 400-channel pulse-height analyser.
The study was carried out on six men. Each had been given from 0-U to 1 LCi of 59Fe intravenously some weeks earlier and red cell incorporation of 59Fe was measured at 14 days after administration. Daily body 59Fe loss was measured in all patients by the techniques we have previously described (Will and Boddy, 1967) . All patients were suffering from severe chronic renal failure secondary to chronic glomerulonephritis, chronic pyelonephritis, or polycystic disease of the kidneys.
All had creatinine clearances of 4 ml per minute or less. At some stage all had received regular dialysis therapy with a Kolff twin-coil artificial kidney. During the course of the study both Chron-a-coils and Ultra-flo-100 coils (BaxterTravenol) were used. Dialysis was performed either twice or thrice weekly as noted. Each dialysis was of 10 hours' duration.
